Patent application number | Description | Published |
20100274019 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE - Methods are provided which include converting oripavine to other opiates, including converting oripavine to naltrexone, buprenorphine, 14-hydroxymorphinone and/or converting 14-hydroxymorphinone to oxymorphone. Purification and salt formation are optionally included. | 10-28-2010 |
20110009634 | PROCESS FOR PREPARING OXYMORPHONE - Methods are provided which include converting oripavine to other opiates, including converting oripavine to 14-hydroxymorphinone and/or converting 14-hydroxymorphinone to oxymorphone. Purification and salt formation are optionally included. | 01-13-2011 |
20110118466 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE - Methods are provided which include converting oripavine to other opiates, including converting oripavine to naltrexone, buprenorphine, 14-hydroxymorphinone and/or converting 14-hydroxymorphinone to oxymorphone. Purification and salt formation are optionally included. | 05-19-2011 |
20120156290 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE - Methods are provided which include converting oripavine to other opiates, including converting oripavine to naltrexone, buprenorphine, 14-hydroxymorphinone and/or converting 14-hydroxymorphinone to oxymorphone. Purification and salt formation are optionally included. | 06-21-2012 |
20120196888 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE - Methods are provided which include converting oripavine to other opiates, including converting oripavine to naltrexone, buprenorphine, 14-hydroxymorphinone and/or converting 14-hydroxymorphinone to oxymorphone. Purification and salt formation are optionally included. | 08-02-2012 |
20120330017 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE - Methods are provided which include converting oripavine to other opiates, including converting oripavine to naltrexone, buprenorphine, 14-hydroxymorphinone and/or converting 14-hydroxymorphinone to oxymorphone. Purification and salt formation are optionally included. | 12-27-2012 |
20140051861 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE - Methods are provided which include converting oripavine to other opiates, including converting oripavine to naltrexone, buprenorphine, 14-hydroxymorphinone and/or converting 14-hydroxymorphinone to oxymorphone. Purification and salt formation are optionally included. | 02-20-2014 |
Patent application number | Description | Published |
20090214523 | Novel anti-IL13 antibodies and uses thereof - The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis. | 08-27-2009 |
20110014199 | NOVEL ANTI-IL 13 ANTIBODIES AND USES THEREOF - The present invention relates to anti IL13 antibodies that hind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis. | 01-20-2011 |
20120156203 | NOVEL ANTI-IL13 ANTIBODIES AND USES THEREOF - The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis. | 06-21-2012 |
20120164144 | NOVEL ANTI-IL13 ANTIBODIES AND USES THEREOF - The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis. | 06-28-2012 |
20120214971 | NOVEL ANTI-IL13 ANTIBODIES AND USES THEREOF - The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis. | 08-23-2012 |
20130195881 | POTENT, STABLE AND NON-IMMUNOSUPPRESSIVE ANTI-CD4 ANTIBODIES - Novel antibodies and their fragments are disclosed that specifically bind to CD4. Anti-CD4 antibodies are disclosed having amino acid substitutions in the hinge region that prevent intrachain disulfide bond formation resulting in antibody molecules with surprisingly improved bivalent stability. Increased stability facilitates manufacturing and provides increased in vivo stability. Antibodies are also disclosed that have amino acid substitutions that reduce binding to Fc receptor and ADCC activity that also result in a surprising effect on CD4 internalization. In addition, genes for such antibodies are disclosed that have been modified such that they have increased expression over their unmodified counterparts. | 08-01-2013 |
20140105897 | Novel Anti-IL13 Antibodies and Uses Thereof - The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis. | 04-17-2014 |
Patent application number | Description | Published |
20100120788 | IDENTIFICATION OF POLYNUCLEOTIDES FOR PREDICTING ACTIVITY OF COMPOUNDS THAT INTERACT WITH AND/OR MODULATE PROTEIN TYROSINE KINASES AND/OR PROTEIN TYROSINE KINASE PATHWAYS IN PROSTATE CELLS - The present invention describes polynucleotides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., prostate cell lines, to treatment with compounds that interact with and modulate, e.g., inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Eph receptors. These polynucleotides have been shown to have utility in predicting the resistance and sensitivity of prostate cell lines to the compounds. The expression level or phosphorylation status of some polynucleotides is regulated by treatment with a particular protein tyrosine kinase inhibitor compound, thus indicating that these polynucleotides are involved in the protein tyrosine kinase signal transduction pathway, e.g., Src tyrosine kinase. Such polynucleotides, whose expression levels correlate highly with drug sensitivity or resistance and which are modulated by treatment with the compounds, comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., prostate cancer, in which signaling through the protein tyrosine kinase pathway, such as the Src tyrosine kinase pathway, is involved with the disease process. | 05-13-2010 |
20120220594 | METHODS FOR TREATING CANCER IN PATIENTS HAVING IGF-1R INHIBITOR RESISTANCE - A method for treating cancer comprising identifying a mammal that overexpresses breast cancer resistance protein; and administering to said mammal a pharmaceutical composition comprising a therapeutically effective amount of ixabepilone. In one aspect, the mammal is not administered an agent that is susceptible to breast cancer resistance protein overexpression resistance. In another aspect, the cancer is a solid tumor. | 08-30-2012 |
20140309229 | METHODS FOR SELECTING AND TREATING CANCER IN PATIENTS WITH IGF-1R/IR INHIBITORS - The present invention relates generally to the field of pharmacogenomics, and more specifically to methods and procedures to determine drug sensitivity in patients to allow the identification of individualized genetic profiles which will aid in selecting cancer patients that are responsive to IGF-1R/IR inhibition. | 10-16-2014 |
Patent application number | Description | Published |
20100028207 | CUVETTE-BASED APPARATUS FOR BLOOD COAGULATION MEASUREMENT AND TESTING - An apparatus for measuring blood clotting time includes a blood clot detection instrument and a cuvette for use with the blood clot detection instrument. The cuvette includes a blood sample receptor-inlet; a channel arrangement including at least one test channel for performing a blood clotting time measurement, a sampling channel having at least one surface portion that is hydrophilic, communicating with the blood sample receptor-inlet and the at least one test channel, and a waste channel having at least one surface portion that is hydrophilic, communicating with the sampling channel; and a vent opening communicating with the sampling channel. The sampling channel, the vent opening and the waste channel, coact to automatically draw a requisite volume of a blood sample deposited at the blood receptor-inlet, into the sampling channel. More specifically, air compressed within the blood clot detection instrument, the at least one test channel of the cuvette, and the section of the sampling channel extending beyond the vent opening of the cuvette, coacts with the waste channel to cause a leading edge of the blood sample drawn into the sampling channel from the blood receptor-inlet, to pull back within the sampling channel and uncover an optical sensor in of the blood clot detection instrument. The uncovering of the optical sensor activates a pump module of the blood clot detection instrument, which draws the requisite volume of the blood sample into the at least one test channel. | 02-04-2010 |
20130017126 | Cuvette-Based Apparatus for Blood Coagulation Measurement and Testing - An apparatus for measuring blood clotting time includes a blood clot detection instrument and a cuvette for use with the blood clot detection instrument. The cuvette includes a blood sample receptor-inlet; a channel arrangement including at least one test channel for performing a blood clotting time measurement, a sampling channel having at least one surface portion that is hydrophilic, communicating with the blood sample receptor-inlet and the at least one test channel, and a waste channel having at least one surface portion that is hydrophilic, communicating with the sampling channel; and a vent opening communicating with the sampling channel. The sampling channel, the vent opening and the waste channel, coact to automatically draw a requisite volume of a blood sample deposited at the blood receptor-inlet, into the sampling channel. | 01-17-2013 |
20140161668 | Cuvette-Based Apparatus for Blood Coagulation Measurement and Testing - An apparatus for measuring blood clotting time includes a blood clot detection instrument and a cuvette for use with the blood clot detection instrument. The cuvette includes a blood sample receptor-inlet; a channel arrangement including at least one test channel for performing a blood clotting time measurement, a sampling channel having at least one surface portion that is hydrophilic, communicating with the blood sample receptor-inlet and the at least one test channel, and a waste channel having at least one surface portion that is hydrophilic, communicating with the sampling channel; and a vent opening communicating with the sampling channel. The sampling channel, the vent opening and the waste channel, coact to automatically draw a requisite volume of a blood sample deposited at the blood receptor-inlet, into the sampling channel. | 06-12-2014 |
Patent application number | Description | Published |
20090202629 | Controlled release hydrocodone formulations - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 08-13-2009 |
20110038927 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 02-17-2011 |
20110262532 | Controlled Release Hydrocodone Formulations - A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C | 10-27-2011 |
20120263788 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 10-18-2012 |
20130158061 | CONTROLLED RELEASE HYDROCODONE - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 06-20-2013 |
20130295177 | CONTROLLED RELEASE HYDROCODONE - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 11-07-2013 |
20130302418 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 11-14-2013 |
20140112981 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS - A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C | 04-24-2014 |
20140199394 | CONTROLLED RELEASE HYDROCODONE - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 07-17-2014 |
20140271840 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS - A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C | 09-18-2014 |
20140377348 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS - A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C | 12-25-2014 |
20150037409 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 02-05-2015 |
Patent application number | Description | Published |
20090075035 | PREPARING NANOPARTICLES AND CARBON NANOTUBES - Apparatus and methods for forming the apparatus include nanoparticles, catalyst nanoparticles, carbon nanotubes generated from catalyst nanoparticles, and methods of fabrication of such nanoparticles and carbon nanotubes. | 03-19-2009 |
20100135937 | METAL OXIDE NANOCRYSTALS: PREPARATION AND USES - Nanocrystalline forms of metal oxides, including binary metal oxide, perovskite type metal oxides, and complex metal oxides, including doped metal oxides, are provided. Methods of preparation of the nanocrystals are also provided. The nanocrystals, including uncapped and uncoated metal oxide nanocrystals, can be dispersed in a liquid to provide dispersions that are stable and do not precipitate over a period of time ranging from hours to months. Methods of preparation of the dispersions, and methods of use of the dispersions in forming films, are likewise provided. The films can include an organic, inorganic, or mixed organic/inorganic matrix. The films can be substantially free of all organic materials. The films can be used as coatings, or can be used as dielectric layers in a variety of electronics applications, for example as a dielectric material for an ultracapacitor, which can include a mesoporous material. Or the films can be used as a high-K dielectric in organic field-effect transistors. In various embodiments, a layered gate dielectric can include spin-cast (e.g., 8 nm-diameter) high-K BaTiO | 06-03-2010 |
20120126199 | PREPARING NANOPARTICLES AND CARBON NANOTUBES - Apparatus and methods for forming the apparatus include nanoparticles, catalyst nanoparticles, carbon nanotubes generated from catalyst nanoparticles, and methods of fabrication of such nanoparticles and carbon nanotubes. | 05-24-2012 |
Patent application number | Description | Published |
20100209936 | Novel recombinant 15-kDa polypeptide and use of same in detecting human infection with Bartonella henselae - Disclosed are the cloning and expression of a novel antigen of | 08-19-2010 |
20110053189 | Type IV secretion system proteins in sero-detection of Anaplasma phagocytophium - Disclosed are two (2) proteins in the Type IV Secretion System (TIVSS) in | 03-03-2011 |
20110076699 | Hemolysin and its protein fragments in sero-detection of anaplasma phagocytophilum - Disclosed is the cloning, expression and purification of a hemolysin protein and its protein fragments in | 03-31-2011 |
20110143377 | Protein fragments of virB10 and sero-detection of anaplasma phagocytophium - Disclosed are cloning and expression of a plurality of protein fragments of virB10, a Type IV Secretion System (TIVSS) in | 06-16-2011 |
20120058495 | Recombinant fragments and synthetic peptides of 17-kDa polypeptide useful in detecting Bartonella henselae - The present disclosure describes recombinant and synthetic polypeptides of | 03-08-2012 |
20120070837 | CIP2A as a biomarker in detection of cervical cancer - The present invention provides methods and compositions for detecting cervical cancer in a human. The present invention provides CIP2A as a biomarker detectable in a biological sample from cervix of an individual, an increased expression of same is an indication of cervical cancer in the individual. CIP2A mRNA or protein can both serve as reliable biomarkers. In one embodiment, the present invention provides a combined use of CIP2A with at least one additional biomarker selected from the group consisting of Ki67, TOP2A, MCM2, MCM5, p14 | 03-22-2012 |
20120183979 | PROTEIN FRAGMENTS OF VIRB10 AND SERO-DETECTION OF ANAPLASMA PHAGOCYTOPHILUM - Disclosed are cloning and expression of a plurality of protein fragments of virB10, a Type IV Secretion System (TIVSS) in | 07-19-2012 |
20120288882 | TYPE IV SECRETION SYSTEM PROTEINS IN SERO-DETECTION OF ANAPLASMA PHAGOCYTOPHILUM - Disclosed are two (2) proteins in the Type IV Secretion System (TIVSS) in | 11-15-2012 |
20130040323 | DETECTION KIT CONTAINING A NOVEL RECOMBINANT 15-kDA POLYPEPTIDE USEFUL FOR DETECTING HUMAN INFECTION WITH BARTONELLA HENSELAE - Disclosed are the cloning and expression of a novel antigen of | 02-14-2013 |
20130115599 | INCREASED CIP2A EXPRESSION AND BLADDER CANCER IN HUMANS - The present invention provides a method of detecting CIP2A protein in a bladder tissue. Methods and compositions are provided herein for detecting and diagnosing bladder cancer by obtaining a bladder tissue from a human subject suspected of bladder cancer, followed by detecting CIP2A protein or mRNA levels in the bladder tissue using Western blot analysis or ELISA to specifically detect CIP2A protein or qRT-PCR to specifically detect CIP2A mRNA. The present method permits specific detection of CIP2A protein or mRNA in bladder tissue as a biomarker for bladder cancer in humans. | 05-09-2013 |
20130189715 | Hemolysin and its Protein Fragments in Sero-Detection of Anaplasma Phagocytophilum - Disclosed is the cloning, expression and purification of a hemolysin protein and its protein fragments in | 07-25-2013 |
20140141457 | DETECTION KIT CONTAINING A NOVEL RECOMBINANT 15-kDA POLYPEPTIDE USEFUL FOR DETECTING HUMAN INFECTION WITH BARTONELLA HENSELAE - Disclosed are the cloning and expression of a novel antigen of | 05-22-2014 |
Patent application number | Description | Published |
20090281321 | EXO- AND DIASTEREO- SELECTIVE SYNTHESES OF HIMBACINE ANALOGS - This application discloses a novel process for the preparation of himbacine analogs useful as thrombin receptor antagonists. The process is based in part on the use of a base-promoted dynamic epimerization of a chiral nitro center. The chemistry taught herein can be exemplified by the following: | 11-12-2009 |
20100267947 | EXO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS - This application discloses a novel process for the synthesis of himbacine analogs, as well as the compounds produced thereby. The synthesis proceeds by alternative routes including the cyclic ketal amide route, the chiral carbamate amide route, and the chiral carbamate ester route. The compounds produced thereby are useful as thrombin receptor antagonists. The chemistry disclosed herein is exemplified in the following synthesis sequence: | 10-21-2010 |
20110251392 | EXO- AND DIASTEREO- SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS - This application discloses a novel process for the preparation of himbacine analogs useful as thrombin receptor antagonists. The process is based in part on the use of a base-promoted dynamic epimerization of a chiral nitro center. The chemistry taught herein can be exemplified by the following: | 10-13-2011 |
20120142914 | EXO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS - This application discloses a novel process for the synthesis of himbacine analogs, as well as the compounds produced thereby. The synthesis proceeds by alternative routes including the cyclic ketal amide route, the chiral carbamate amide route, and the chiral carbamate ester route. The compounds produced thereby are useful as thrombin receptor antagonists. The chemistry disclosed herein is exemplified in the following synthesis sequence: | 06-07-2012 |
20120296093 | EXO- AND DIASTEREO- SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS - This application discloses a novel process for the preparation of himbacine analogs useful as thrombin receptor antagonists. The process is based in part on the use of a base-promoted dynamic epimerization of a chiral nitro center. The chemistry taught herein can be exemplified by the following: | 11-22-2012 |
20120302745 | EXO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS - This application discloses a novel process for the synthesis of himbacine analogs, as well as the compounds produced thereby. The synthesis proceeds by alternative routes including the cyclic ketal amide route, the chiral carbamate amide route, and the chiral carbamate ester route. The compounds produced thereby are useful as thrombin receptor antagonists. The chemistry disclosed herein is exemplified in the following synthesis sequence: | 11-29-2012 |
Patent application number | Description | Published |
20100068544 | WATER RESISTANT ADHESIVE AND METHODS OF USE - The invention provides the art with an adhesive that may advantageously be used in the manufacture of water resistant paperboard products, such as laminated board and corrugated board. The adhesive has the required tack, water resistance and viscosity that allows its use at commercial speeds in a cold corrugating process. | 03-18-2010 |
20130052379 | Starch-Based Adhesive Compositions and Use Thereof - An improved adhesive composition having increased bond strength between a celluosic board and plastic film substrate is provided. The adhesive composition having improved adhesion includes a modified starch component, polyethylenimine and water. Articles having improved adhesion and methods of making the articles having improved adhesion are also provided. | 02-28-2013 |
20130160945 | ADHESIVE HAVING INSULATIVE PROPERTIES - An improved adhesive composition having increased insulative properties is provided. The adhesive composition having improved insulative properties includes a starch component; an alkaline component; sodium tetraborate; water; and a plurality of expandable microspheres. Products having improved insulation capabilities and methods of making the products having improved insulation capabilities are also provided. The present adhesive and products including the adhesive is environmentally friendly. | 06-27-2013 |
20140087109 | ADHESIVE HAVING STRUCTURAL INTEGRITY AND INSULATIVE PROPERTIES - An adhesive composition that provides improved structural integrity and insulative properties when applied to a substrate is provided. The adhesive composition includes an emulsion-based polymer, a plurality of microspheres; and optionally, water and plasticizer. | 03-27-2014 |
20140087177 | WATERBORNE ADHESIVES FOR REDUCED BASIS WEIGHT MULTILAYER SUBSTRATES AND USE THEREOF - The adhesive composition comprising emulsion polymers and microspheres and articles made therefrom are provided. The adhesive is particularly suitable for packages for consumer products that provide sufficient strength and thermal insulation while reducing the overall basis weight of the substrates. | 03-27-2014 |
20140141185 | HOT MELT ASSIST WATERBORNE ADHESIVES AND USE THEREOF - A hot melt assist waterborne adhesive having high amplitude bead profile and higher heat resistance is provided. The hot melt assist waterborne adhesive includes an emulsion polymer, a preservative, a plurality of pre-expanded hollow microspheres and water. The hot melt assist waterborne adhesive is suitable as a partial or complete replacement to hot melt adhesives for use in converting paper and packaging process. | 05-22-2014 |
20140238586 | ADHESIVE HAVING INSULATIVE PROPERTIES - An improved adhesive composition having increased insulative properties is provided. The adhesive composition having improved insulative properties includes a starch component; an alkaline component; sodium tetraborate; water; and a plurality of expandable microspheres. Products having improved insulation capabilities and methods of making the products having improved insulation capabilities are also provided. The present adhesive and products including the adhesive is environmentally friendly. | 08-28-2014 |
Patent application number | Description | Published |
20100143422 | Microcapsules Containing Active Ingredients - The present invention relates to a microcapsule particle composition that is composed of a sol-gel material. The microcapsule particle composition is well suited for personal care and cleaning products. | 06-10-2010 |
20100247660 | Microcapsules Containing Active Ingredients - The present invention relates to a microcapsule particle composition that is composed of a sol-gel material. The microcapsule particle composition is well suited for personal care and cleaning products. | 09-30-2010 |
20120003176 | HYDROGEL-FORMING COMPOSITION COMPRISING NATURAL AND SYNTHETIC SEGMENTS - A hydrogel composition is formed from a natural polymer derivative having a plurality of cross-linkable units depending therefrom, and a synthetic polymer derivative having a plurality of cross-linkable units depending therefrom, said natural and synthetic polymer derivatives having hydrolysable units disposed between the polymer backbone of said derivative and at least some of said cross-linkable units. The use of a combination of natural and synthetic polymers provides for biodegradability of the hydrogel, along with mechanical properties such as strength and elasticity. | 01-05-2012 |
20120003192 | HYDROGEL-FORMING COMPOSITION COMPRISING PROTEIN AND NON-PROTEIN SEGMENTS - A hydrogel-forming composition is formed from a protein polymer derivative having a plurality of cross-linkable units depending therefrom, and a non-protein polymer derivative having a plurality of cross-linkable units depending therefrom, said non-protein polymer derivatives having hydrolysable units disposed between the polymer backbone of said derivative and at least some of said cross-linkable units. The use of a combination of protein and non-protein polymers provides for biodegradability of the hydrogel by hydrolysis of the hydrolysable units and/or enzymatic degradation of the proteins, along with mechanical properties such as strength and elasticity. | 01-05-2012 |
20120020932 | THERMOSENSITIVE HYDROGEL COMPOSITION AND METHOD - A hydrogel-forming composition is provided that comprises an extracellular matrix protein, hyaluronic acid, and a thermosensitive biocompatible polymer such as methylcellulose. The hydrogels can provide a therapeutic effect; further, the hydrogels may comprise an optional therapeutic agent such as cells or a pharmaceutical composition. The composition may be injected to an area in need of treatment by the therapeutic agent. The composition may form a gel at about 37° C., such that the gel maintains the therapeutic agent in the area of the body in need of such treatment. | 01-26-2012 |
20120148644 | Encapsulated Active Materials - The invention relates to microcapsule composition which encapsulates active material that may be used in products for washing and cleaning and/or care and protection of animate or inanimate. The invention also relates to polyurethane and polyurea microcapsules that may be modified with additional polymers. | 06-14-2012 |
20120237578 | Microcapsules produced from blended sol-gel precursors and method for producing the same - The present invention features microcapsule particles with an oil or aqueous liquid core, and shell composed of a blend of metal or semi-metal oxide polymers. Methods for preparing and using the microcapsule particles in personal care, therapeutic, cosmetic and cosmeceutic products are also provided. | 09-20-2012 |
20120294821 | Low Volatile Reactive Malodor Counteractives and Methods of Use Thereof - The present invention is a compound for counteracting thiol- and amine-based malodors in consumer, industrial and textile products. | 11-22-2012 |
20130101544 | LOW VOLATILE REACTIVE MALODOR COUNTERACTIVES AND METHODS OF USE THEREOF - The present invention provides a novel compound for counteracting amine-based malodor in consumer, industrial and textile products. | 04-25-2013 |
20130101545 | Low Volatile Reactive Malodor Counteractives and Methods of Use Thereof - The present invention provides a novel compound for counteracting amine-based malodor in consumer, industrial and textile products. | 04-25-2013 |
20130344027 | MULTI-FUNCTIONAL POLYMERIC MATERIALS AND THEIR USES - Multifunctional polymers are disclosed having a smart segment and a biodegradable segment. Advantageously, the biodegradable segment includes a hydrophilic segment and a hydrophobic segment. Embodiments include combining the multifunctional polymeric material with a biologically active substance in an aqueous loading environment and administering the composition as a drug delivery vehicle to a human subject. | 12-26-2013 |
Patent application number | Description | Published |
20080200459 | TETRAHYDROQUINOLINE CANNABINOID RECEPTOR MODULATORS - The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: | 08-21-2008 |
20100048612 | BICYCLIC HETEROCYCLES AS CANNABINOID-1 RECEPTOR MODULATORS - The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula: | 02-25-2010 |
20110034468 | TRIAZOLO COMPOUNDS USEFUL AS DGAT1 INHIBITORS - Disclosed are triazolopyridine compounds of Formula (I), including pharmaceutically acceptable salts thereof. Also, disclosed are methods of using the compound in the treatment of obesity, dyslipidemia, diabetes and atherosclerosis, and to pharmaceutical compositions comprising at least one compound of Formula (I) or a stereoisomer or pharmaceutically acceptable salt thereof. | 02-10-2011 |
20110104315 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS - The invention provides for compounds of formula I | 05-05-2011 |
20130184262 | DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF - The present invention provides compounds of Formula (I): | 07-18-2013 |
20130184284 | DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF - The present invention provides compounds of Formula (I): | 07-18-2013 |
20130345123 | SUBSTITUTED ADIPIC ACID AMIDES AND USES THEREOF - The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein A is a five to eight membered monocyclic or a nine to twelve membered bicyclic heterocyclic ring, as further defined herein; Y is S, CH | 12-26-2013 |
Patent application number | Description | Published |
20090291112 | Allograft osteochondral plug combined with cartilage particle mixture - An allograft osteochondral plug is combined with a mixture that includes freeze-milled cartilage particles, and such combination is used to repair defects in articular cartilage. The plug includes an subchondral bone portion and an integral overlying cartilage cap which is treated to remove cellular debris and proteoglycans. At least a portion of the plug has a lateral dimension selected to form an interference fit against a tissue layer exposed as a result of a bore formed in a defect area in articular cartilage of a host. The cartilage particle mixture is placed adjacent at least a portion of the plug for promoting cartilage cell migration into (i.e., from the adjacent host cartilage) and proliferation in the bore, and for enhancing tissue integration between the plug and patient (i.e., host) tissue when the plug is inserted into the bore. Methods for surgical implantation of the plug into a patient are also disclosed. | 11-26-2009 |
20090319045 | Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles - Constructs that are at least partially constructed of allograft cancellous bone are disclosed, along with cartilage particles that may be used with the constructs for repairing articular cartilage defects. A multi-piece construct includes a base member, a cap member and at least one pin that secures the cap member to the base member. The base member may be constructed of mineralized cancellous bone, and is used to replace the subchondral bone removed when a surgeon cuts a bore in the area of an adjacent cartilage defect. The base member includes a blind bore and first and second through-going transverse bores in opposite sides of a wall of the base member. The cap member includes an upper section that has a thickness that is similar to that of a patient's surrounding articular cartilage layer and a stem depending from the upper section that is dimensioned to be received in and by the blind bore of the base member. The stem includes a transverse through-going bore, which may be aligned with the transverse through-going bores of the base member to receive the pin therein when the construct has been assembled. The cap member is at least partially formed of demineralized allograft cancellous bone, into which a mixture containing lyophilized, freeze-milled allograft cartilage particles may be infused for the repair of articular cartilage defects. The cartilage particles have a size within a range of from about 10 microns to about 210 microns. | 12-24-2009 |
20100015202 | CANCELLOUS CONSTRUCT WITH SUPPORT RING FOR REPAIR OF OSTEOCHONDRAL DEFECTS - The invention is directed toward an osteochondral repair assembly comprising a shaped allograft construct comprising an unbalanced barbell-shaped cylindrical cancellous bone primary member formed with a mineralized cylindrical base section having a smaller diameter cylindrical stem leading to a second cylindrical section which is demineralized. A mineralized ring-shaped support member is forced over the compressed demineralized second demineralized the aperture of the ring-shaped member to fit around the stem with one ring surface being adjacent the bottom surface to the second cylindrical section and the opposite ring surface being adjacent the upper surface of the mineralized cylindrical base section. | 01-21-2010 |
20100274362 | Cartilage particle tissue mixtures optionally combined with a cancellous construct - Mixtures, such as gels or pastes, comprising freeze-milled cartilage particles and exogenous growth factors are used for repairing chondral defects. Such mixtures may be applied to constructs comprising cancellous bone for implantation at the defect site. Suitable growth factors include variants of FGF-2, particularly variants that include a sole amino acid substitution for asparagine at amino acid 111 of the β8-β9 loop of the FGF-2 peptide. Such FGF-2 variants are released slowly and continuously at a constant rate from cartilage pastes. In other embodiments, the amino acid substituted for asparigine is glycine. Other variants that may be used include FGF-9 variants having truncated chains and a sole amino acid substitution in the β8-β9 loop of the FGF-9 peptide either for tryptophan at amino acid 144 or for asparagine at amino acid 143. | 10-28-2010 |
20110059178 | Tissue Engineered Meniscus Repair Composition - A meniscus repair composition for application to a meniscus defect site to promote growth of new tissue at the meniscus defect site is provided. The composition comprises: from about 10 to about 50 percent by weight of allograft meniscus particles having an average particle size of from about 10 μm to about 500 μm; a carrier selected from the group consisting of sodium hyaluronate, gelatin, collagen, polyethylene glycol, glycerin, carboxymethylcellulose, dextrose, blood derivatives, aqueous solutions thereof, and mixtures thereof; and a curing agent. The curing agent may be the carrier where the carrier is cross-linkable. When introduced to a defect site in a meniscus and cured, the composition will not flow away from the defect site, and the composition is non-adhering to the defect site after it is cured. | 03-10-2011 |
20110060412 | Tissue Engineered Meniscus Repair Composition - A meniscus repair composition for application to a meniscus injury to promote growth of new tissue at the meniscus injury site is provided. The composition comprises: from about 10 to about 50 percent by weight of allograft meniscus particles having an average particle size of from about 10 μm to about 500 μm; and a carrier comprising a solid fibrin web matrix. When introduced to a defect site in a meniscus, the composition is non-adhering to the defect site. A method for repairing a meniscus injury comprises administering a meniscus repair composition to the injury site. | 03-10-2011 |
20120251609 | DEMINERALIZED CANCELLOUS BONE MATRIX - A demineralized cancellous bone matrix comprising a cancellous bone matrix that has been demineralized is described herein. The demineralized cancellous bone matrix is rigid and has certain dimensions, including a certain length. Implants comprising at least one demineralized cancellous bone matrix are also described. Also disclosed are methods for treating bone having a void or defect in a patient using at least one demineralized cancellous bone matrix. In addition, methods of making a demineralized cancellous bone matrix are disclosed. | 10-04-2012 |
20150037436 | ACELLULAR SOFT TISSUE-DERIVED MATRICES AND METHODS FOR PREPARING SAME - An acellular soft tissue-derived matrix includes a collagenous tissue that has been delipidated and decellularized. Adipose tissue is among the soft tissues suitable for manufacturing an acellular soft tissue-derived matrix. Exogenous tissuegenic cells and other biologically-active factors may be added to the acellular matrix. The acellular matrix may be provided as particles, a slurry, a paste, a gel, or in some other form. The acellular matrix may be provided as a three-dimensional scaffold that has been reconstituted from particles of the three-dimensional tissue. The three-dimensional scaffold may have the shape of an anatomical feature and serve as a template for tissue repair or replacement. A method of making an acellular soft tissue-derived matrix includes steps of removing lipid from the soft tissue by solvent extraction and chemical decellularization of the soft tissue. | 02-05-2015 |
Patent application number | Description | Published |
20100227873 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF - The present invention provides compounds of Formula (I): | 09-09-2010 |
20110207734 | Azine Derivatives and Methods of Use Thereof - The present invention relates to Azine Derivatives, pharmaceutical compositions comprising the Azine Derivatives and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. | 08-25-2011 |
20110319434 | Bicyclic Heterocyclic Derivatives and Methods of Use Thereof - The present invention relates to novel Bicyclic Heterocyclic Derivatives, pharmaceutical compositions comprising the Bicyclic Heterocyclic Derivatives and the use of these compounds for treating or preventing treating allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a cognitive disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. | 12-29-2011 |